Regenxbio

OverviewSuggest Edit

Regenxbio is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders, as well as clinical trails in therapeutic areas.
TypePublic
Founded2009
HQRockville, MD, USMap
Websiteregenxbio.com
Employee Ratings4.6More
Overall CultureAMore
View Jobs (32)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)257(+34%)
Job Openings32
Revenue (FY, 2020)$154.6 M(+339%)
Share Price (Nov 2021)$37.8
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Regenxbio

Olivier Danos

Olivier Danos

Chief Scientific Officer
Allan Fox

Allan Fox

Chairman of the Board
Vit Vasista

Vit Vasista

Chief Financial Officer
Ken Mills

Ken Mills

Director, President and Chief Executive Officer
Jerry Karabelas

Jerry Karabelas

Lead Independent Director
Ram Palanki

Ram Palanki

Senior Vice President of Commercial Strategy and Operations
Show more

Regenxbio Office Locations

Regenxbio has an office in Rockville
Rockville, MD, US (HQ)
9600 Blackwell Rd #210
Rockville, MD, US
9804 Medical Center Dr
Show all (2)

Regenxbio Financials and Metrics

Regenxbio Revenue

Regenxbio's revenue was reported to be $154.57 m in FY, 2020
USD

Revenue (Q1, 2021)

18.9m

Gross profit (Q1, 2021)

14.0m

Gross profit margin (Q1, 2021), %

74.3%

Net income (Q1, 2021)

(50.1m)

EBIT (Q1, 2021)

(44.0m)

Market capitalization (12-Nov-2021)

1.6b

Closing stock price (12-Nov-2021)

37.8

Cash (31-Mar-2021)

291.5m

EV

1.4b
Regenxbio's current market capitalization is $1.6 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

7.6m4.6m10.4m218.5m35.2m154.6m

Cost of goods sold

98.0k98.0k6.0k8.2m35.7m

Gross profit

7.5m4.5m10.4m27.0m118.9m

Gross profit Margin, %

99%98%100%77%77%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.1m393.0k2.4m125.0k455.0k6.6m1.3m132.4m40.0m5.3m884.0k7.9m14.7m17.6m16.6m98.9m18.9m

Cost of goods sold

44.0k30.0k49.0k22.0k6.0k3.9m517.0k29.0k1.9m2.5m3.4m4.7m17.4m4.9m

Gross profit

1.1m363.0k2.3m103.0k6.6m36.2m4.8m855.0k6.0m12.2m14.2m11.9m81.5m14.0m

Gross profit Margin, %

96%92%98%82%100%90%90%97%76%83%81%72%82%74%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

54.1m24.8m46.7m75.6m69.5m338.4m

Accounts Receivable

2.1m1.0m473.0k8.6m38.1m43.0m

Prepaid Expenses

1.0m1.8m5.3m5.7m6.5m10.5m

Current Assets

118.1m93.4m168.0m337.9m345.0m531.2m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

205.3m35.5m30.1m28.1m82.0m57.6m59.9m71.9m106.9m142.4m55.9m55.1m79.6m69.4m94.2m93.2m291.5m

Accounts Receivable

2.0m783.0k679.0k228.0k50.0k884.0k26.0m739.0k2.6m8.4m9.7m19.2m44.5m42.9m122.1m41.0m

Prepaid Expenses

1.4m1.2m1.5m2.2m1.8m2.4m3.2m4.7m6.3m6.0m6.9m7.4m9.7m16.1m13.8m

Current Assets

215.5m105.6m97.9m96.6m148.8m165.8m172.2m262.7m293.3m386.4m303.9m359.5m360.2m338.2m329.1m387.0m498.6m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(22.8m)(63.0m)(73.2m)99.9m(94.7m)(111.2m)

Depreciation and Amortization

80.0k544.0k2.7m4.0m7.2m8.4m

Accounts Payable

590.0k186.0k2.6m(218.0k)1.5m3.9m

Cash From Operating Activities

(22.5m)(48.6m)(58.0m)104.6m(107.7m)(54.1m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(17.6m)(10.8m)(25.2m)(43.4m)(22.0m)(36.5m)(57.2m)104.2m114.8m95.6m(32.2m)(33.7m)(68.3m)(40.0m)(73.8m)(65.0m)(50.1m)

Depreciation and Amortization

43.0k48.0k104.0k264.0k554.0k1.3m2.0m834.0k1.7m2.7m1.6m3.4m5.2m2.0m4.1m6.3m1.9m

Accounts Payable

317.0k(182.0k)930.0k3.6m2.5m2.7m1.1m477.0k(340.0k)156.0k316.0k1.8m5.3m3.1m4.1m9.9m278.0k

Cash From Operating Activities

(18.1m)(7.9m)(16.3m)(28.1m)(17.5m)(27.0m)(44.2m)58.1m128.3m108.8m(29.3m)(53.0m)(82.2m)(35.6m)(57.1m)(93.5m)(41.1m)
show all
USDQ3, 2015

Financial Leverage

1 x
Show all financial metrics

Regenxbio Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

Regenxbio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Regenxbio Online and Social Media Presence

Regenxbio's Trends

Embed Graph

Regenxbio Company Culture

  • Overall Culture

    A

    85/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A-

    84/100

Learn more on Comparably

Regenxbio News and Updates

June 05, 2018

Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR

This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…
May 06, 2018

3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises

April 18, 2018

OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner

April 17, 2018

Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary

April 10, 2018

BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved

December 21, 2017

Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday

Regenxbio Blogs

November 12, 2021

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021 Content Import Fri, 11/12/2021 - 16:33 REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic…
November 09, 2021

REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie

REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie Content Import Tue, 11/09/2021 - 16:13 REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie November 9, 2021 at 4:05 PM EST This release is a backfill from a New…
November 02, 2021

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights Content Import Tue, 11/02/2021 - 16:10 REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights November 2, 2021 at 4:05 PM EDT This release is a backfil…
October 26, 2021

REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Oct. 26, 2021 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, November 2, 2021 , at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2021 , and recent operational highlights.
October 09, 2021

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting Content Import Sat, 10/09/2021 - 11:23 REGENXBIO Presents Positive Initial Data…
October 01, 2021

REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting

REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting Content Import Fri, 10/01/2021 - 15:47 REGENXBIO Presents Positive Initial …
Show more

 Regenxbio Frequently Asked Questions

  • When was Regenxbio founded?

    Regenxbio was founded in 2009.

  • Who are Regenxbio key executives?

    Regenxbio's key executives are Olivier Danos, Allan Fox and Vit Vasista.

  • How many employees does Regenxbio have?

    Regenxbio has 257 employees.

  • What is Regenxbio revenue?

    Latest Regenxbio annual revenue is $154.6 m.

  • What is Regenxbio revenue per employee?

    Latest Regenxbio revenue per employee is $601.4 k.

  • Who are Regenxbio competitors?

    Competitors of Regenxbio include Evotec, BlueRock Therapeutics and OXGENE.

  • Where is Regenxbio headquarters?

    Regenxbio headquarters is located at 9600 Blackwell Rd #210, Rockville.

  • Where are Regenxbio offices?

    Regenxbio has an office in Rockville.

  • How many offices does Regenxbio have?

    Regenxbio has 2 offices.